加强基于大数据的药物性肝损伤的科学研究和监管

茅益民

doi:10.3969/j.issn.1001-5256.2018.06.005

加强基于大数据的药物性肝损伤的科学研究和监管

DOI: 10.3969/j.issn.1001-5256.2018.06.005

茅益民

上海交通大学医学院附属仁济医院,上海市消化疾病研究所

基金项目:

“十三五”科技重大专项(2017ZX09304016)；国家自然科学基金课题(81670524)；

详细信息

中图分类号: R575
计量
- 文章访问数: 335
- HTML全文浏览量: 32
- PDF下载量: 132
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-31
- 出版日期: 2018-06-20

Strengthening the scientific research and supervision of drug-induced liver injury based on big data

Mao YiMin

Shanghai Institute of Digestive Diseases, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Research funding:

摘要

摘要: 药物性肝损伤(DILI)是重要的药源性疾病之一,其临床表型复杂,往往具有不可预测性。由于涉及的药物种类繁多,尤其是复杂的人群异质性,决定了针对DILI的科学研究和监管具有极大的挑战性。目前对于DILI的认知,多来源于国际上长期随访的数据库。然而,DILI领域仍有大量未被满足的临床需求。加强基于大数据DILI的科学研究是更好认知DILI的有效措施,也是科学监管的前提。
- 药物性肝损伤 /
- 数据库
Abstract: Drug-induced liver injury (DILI) is one of the most important drug-induced diseases and has complex clinical phenotypes, which leads to its unpredictability. The involvement of many types of drugs and complex population heterogeneity pose great challenges to the supervision of scientific research on DILI. Most of our knowledge of DILI comes from the international databases of long-term follow-up.However, there are still many unmet clinical needs in the field of DILI. Strengthening the scientific research on drug-induced liver injury based on big data helps us to understand DILI better and it is the premise for scientific supervision.
- drug-induced liver injury /
- database

HTML全文

参考文献(16)

[1] HOOFNAGLE JH, SERRANO J, KNOBEN JE, et al.Liver Tox:A website on drug-induced liver injury[J].Hepatology, 2013, 57 (3) :873-874.

[2]MAO YM.Hepa Tox:A professional network platform promoting the clinical and translational research on drug-induced liver injury in China[J].Chin Hepatol, 2014, 19 (8) :575-576. (in Chinese) 茅益民.Hepa Tox:促进中国药物性肝损伤临床和转化研究的专业网络平台[J].肝脏, 2014, 19 (8) :575-576.

[3]KAPLOWITZ N.Idiosyncratic drug hepatotoxicity[J].Nat Rev Drug Discov, 2005, 4:489-499.

[4] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG clinical guideline:The diagnosis and management of idiosyncratic druginduced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.

[5]Drug-Induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[6]ROCHON J, PROTIVA P, SEEFF LB, et al.Reliability of the RUCAM for assessing causality in drug-induced liver injury[J].Hepatology, 2008, 48 (4) :1175-1183.

[7]HOOFNAGLE JH, SERRANO J, KNOBEN JE, et al.Liver Tox:A website on drug-induced liver injury[J].Hepatology, 2013, 57 (3) :873-874.

[8]LUCENA M, MOLOKHIA M, SHEN Y, et al.Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles[J].Gastroenterology, 2011, 141 (1) :338-347.

[9]DALY AK, DONALDSON PT, BHATNAGAR P, et al.HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin[J].Nat Genet, 2009, 41 (7) :816-819.

[10]NICOLETTI P, AITHAL GP, BJORNSSON ES, et al.Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study[J].Gastroenterology, 2017, 152 (5) :1078-1089.

[11]HAYASHI PH, ROCKEY DC, FONTANA RJ, et al.Death and liver transplantation within 2 years of onset of drug-induced liver injury[J].Hepatology, 2017, 66 (4) :1275-1285.

[12]FONTANA RJ, HAYASHI PH, GU J, et al.Idiosyncratic druginduced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J].Gastroenterology, 2014, 147 (1) :96-108.

[13]CHALASANI N, BONKOVSKY HL, FONTANA R, et al.Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352.

[14]STUTCHFIELD BM, ANTOINE DJ, MACKINNON AC, et al.CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure[J].Gastroenterology, 2015, 149 (7) :1896-1909.

[15]CHEN M, BORLAK J, TONG W.A model to predict severity of drug-induced liver injury in humans[J].Hepatology, 2016, 64 (3) :931-940.

[16]BENESIC A, LEITL A, GERBES AL.Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury[J].Gut, 2016, 65 (9) :1555-1563.

施引文献

资源附件(0)

访问统计